·Category 1 new drug ·The world's first CDK2/4/6 inhibitor, indicated for use in combination with fulvestrant for patients with HR+/HER2- locally advanced or metastatic breast cancer who have previously received endocrine therapy ·It provides a novel treatment option for addressing clinical CDK4/6 inhibitor resistance and alleviating myelosuppression

*For contraindications and adverse reactions, please see the package insert

·The first domestic-made biological product in the recombinant human coagulation factor Ⅶa category in China ·The first recombinant human coagulation factor Ⅶa whose efficacy and safety have been confirmed through Phase Ⅲ clinical trials in the Chinese population ·It possesses independently developed technologies for cell culture, separation and purification, and formulation with independent intellectual property rights, with two original patents granted

*For contraindications and adverse reactions, please see the package insert